Adamas Pharmaceuticals Inc (ADMS)

Common Stock

8.22  +0.06 (+0.74%)

After market: 8.3 +0.08 (+0.97%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2018 2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
34.05M
5,873.68%		54.64M
60.47%		74.46M
36.27%		96.04M
EBITDA
YoY % growth
-113.56M
-30.92%		-91.03M
19.84%		-43.31M
52.42%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-115.02M
-30.81%		-92.24M
19.81%		-44.16M
52.12%		N/AN/AN/AN/AN/A
Operating Margin
-337.80%-168.81%-59.31%N/AN/AN/AN/AN/A
EPS
YoY % growth
-4.89
-23.48%		-3.80
22.29%		-2.02
46.84%		-1.04

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 21 Q1 / 22 Q2 / 22 Q3 / 22 Q4 / 22 Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.18
Revenue
Q2Q % growth		28.516M
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/AN/A

Recent Earnings VS Estimates Surprises ()
PeriodReportedEstimateDifferenceSurprise
Q2 2021
Q2Q % growth		 -0.27
27.03%		-0.300.039.76%
Q1 2021
Q2Q % growth		 -0.36
38.98%		-0.520.1630.80%
Q4 2020
Q2Q % growth		 -0.64
22.89%		-0.52-0.12-21.97%
Q3 2020
Q2Q % growth		 -0.42
57.58%		-0.490.0714.41%
Recent Revenue VS Estimates Surprises

Reported revenue can not be compared with estimates as they are in different currencies. Reported data is in USD, while estimates are .

PeriodReportedEstimateDifferenceSurprise
Q3 2021
Q2Q % growth		 25.896M
28.33%		25.263M632.507K2.50%
Q2 2021
Q2Q % growth		 21.972M
16.93%		22.382M-410.084K-1.83%
Q1 2021
Q2Q % growth		 19.31M
33.36%		20.417M-1.107M-5.42%
Q4 2020
Q2Q % growth		 21.01M
28.50%		21.375M-365.232K-1.71%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A